{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:49:02Z","timestamp":1769694542912,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Center Support Grant"},{"name":"Core Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Janssen"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.adro.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T23:28:57Z","timestamp":1548890937000},"page":"337-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Attapol","family":"Pinitpatcharalert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Happersett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gorovets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2018.12.001_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2015.10.049","article-title":"NRG Oncology RTOG 0415: A randomized phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer","volume":"94","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib5","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib6","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.prro.2017.11.008","article-title":"Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?","volume":"8","author":"Gonzalez-Motta","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13014-017-0854-4","article-title":"Clinical workflow for MR-only simulation and planning in prostate","volume":"12","author":"Tyagi","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib9","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1088\/1361-6560\/aa5452","article-title":"Dosimetric and workflow evaluation of first commercial synthetic CT software for clinical use in pelvis","volume":"62","author":"Tyagi","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.adro.2018.12.001_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2005.02.050","article-title":"Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy","volume":"63","author":"Ashman","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2013.02.006","article-title":"Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: A step forward","volume":"86","author":"Kaidar-Person","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase I\/II study of stereotactic ablative radiotherapy including regional lymph node irradiation for patients with high-risk prostate cancer (SATURN): Early results","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib13","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/j.ejso.2016.07.076","article-title":"SPORT high-risk trial: A randomised feasibility study evaluating stereotactic prostate radiotherapy in high-risk localised prostate cancer with or without elective nodal irradiation","volume":"42","author":"Lyons","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","article-title":"Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer","volume":"30","author":"Murthy","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2018.12.001_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.adro.2018.12.001_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fonc.2016.00168","article-title":"Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: Risk-stratification and patterns of failure","volume":"6","author":"Katz","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.adro.2018.12.001_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib22","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/MD.0000000000000290","article-title":"Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: A 5-year follow-up of an investigational study","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.adro.2018.12.001_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fonc.2014.00312","article-title":"SBRT for the primary treatment of localized prostate cancer: The effect of gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines","volume":"4","author":"Bernetich","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib24","first-page":"e395","article-title":"Stereotactic body radiotherapy for clinically localized prostate cancer: Toxicity and biochemical disease-free outcomes from a multi-institutional patient registry","volume":"79","author":"Davis","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.adro.2018.12.001_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fonc.2016.00184","article-title":"The comparison of stereotactic body radiation therapy and intensity-modulated radiation therapy for prostate cancer by NCCN risk groups","volume":"6","author":"Ricco","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2018.12.001_bib26","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ijrobp.2016.02.009","article-title":"Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: Initial dosimetry analysis and patient outcomes","volume":"95","author":"Kotecha","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.12.001_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/0284186X.2017.1288923","article-title":"Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience","volume":"56","author":"Koskela","year":"2017","journal-title":"Acta Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109418302434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109418302434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:36:20Z","timestamp":1762529780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109418302434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2452109418302434"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2018.12.001","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}